NCT04925479
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04925479
Title Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | child
Covered Countries USA | TUR | POL | NLD | ITA | HUN | GRC | FRA | DEU

Facility Status City State Zip Country Details
Indiana UH Riley H for CIU ACTIVE_NOT_RECRUITING Indianapolis Indiana 46202-5167 United States Details
Dana Farber Cancer Institute ACTIVE_NOT_RECRUITING Boston Massachusetts 02215 United States Details
University of Mississippi Medical Center RECRUITING Jackson Mississippi 39216-4505 United States Details
Columbia University Medical Center New York Presbyterian ACTIVE_NOT_RECRUITING New York New York 10032 United States Details
Cinn Children Hosp Medical Center WITHDRAWN Cincinnati Ohio 45229-3039 United States Details
Childrens Hospital of Philadelphia WITHDRAWN Philadelphia Pennsylvania 19104-4399 United States Details
Uni Of Texas MD Anderson Cancer Ctr WITHDRAWN Houston Texas 77024 United States Details
University Of Utah WITHDRAWN Salt Lake City Utah 84132 United States Details
Novartis Investigative Site WITHDRAWN Hangzhou Zhejiang 310052 China Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Beijing 100044 China Details
Novartis Investigative Site WITHDRAWN Shanghai 200127 China Details
Novartis Investigative Site WITHDRAWN Tianjin 300020 China Details
Novartis Investigative Site WITHDRAWN Bordeaux 33076 France Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Lille 59000 France Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Paris 75019 France Details
Novartis Investigative Site WITHDRAWN Poitiers 86021 France Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Erlangen 91054 Germany Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Essen 45147 Germany Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Hamburg 20246 Germany Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Athens 115 27 Greece Details
Novartis Investigative Site WITHDRAWN Budapest 1083 Hungary Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Genova GE 16147 Italy Details
Novartis Investigative Site WITHDRAWN Monza MB 20900 Italy Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Roma RM 00165 Italy Details
Novartis Investigative Site WITHDRAWN Torino TO 10126 Italy Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Yokohama Kanagawa 2328555 Japan Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Shinjuku-ku Tokyo 1608582 Japan Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Osaka 5340021 Japan Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Utrecht 3584 CS Netherlands Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Wroclaw 50-367 Poland Details
Novartis Investigative Site WITHDRAWN Moscow 117198 Russia Details
Novartis Investigative Site WITHDRAWN Saint Petersburg 197022 Russia Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Seoul 03080 South Korea Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Seoul 05505 South Korea Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Khon Kaen THA 40002 Thailand Details
Novartis Investigative Site WITHDRAWN Bangkok 10400 Thailand Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Chiang Mai 50200 Thailand Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Istanbul Fatih 34093 Turkey (Türkiye) Details
Novartis Investigative Site ACTIVE_NOT_RECRUITING Bursa Nilufer 16059 Turkey (Türkiye) Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field